Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPC-2: IMM-101 added to stereotactic radiotherapy for locally advanced pancreatic cancer
2019-000216-29Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- May 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IMM-101 in pancreatic cancer (PC), sponsored by Erasmus MC. Primary endpoints: Phase I safety and feasibility and Phase II efficacy. Started May 2019; status: completed.
02
Drugs
IMM-101
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2019-000216-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000216-29.